trolamine salicylate has been researched along with B16 Melanoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bir Kohli, P; Caplazi, P; Cheng, JH; Deshmukh, G; Dugger, DL; Fong, R; Hamilton, G; Johnson, A; Junttila, MR; Kwon, YC; Lee, WP; Liederer, BM; Lupardus, P; Maltzman, A; McKenzie, BS; Newton, K; Patel, S; Ramaswamy, S; Sujatha-Bhaskar, S; van Lookeren Campagne, M; Varfolomeev, E; Vucic, D; Webster, JD; Wickliffe, KE; Zhang, J | 1 |
1 other study(ies) available for trolamine salicylate and B16 Melanoma
Article | Year |
---|---|
RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases.
Topics: Animals; Arthritis; Cell Death; Cell Line; Cell Line, Tumor; Colitis; Dermatitis; Female; Gene Knock-In Techniques; Humans; Ileitis; Inflammation; Intracellular Signaling Peptides and Proteins; Male; Melanoma, Experimental; Mice; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Receptor-Interacting Protein Serine-Threonine Kinases | 2020 |